Skip to content

Pharmaceutical market research · Mexico and LATAM

Evidence before the decision.

We design the study, run fieldwork on our own physician panel and model the result until it answers your business question.

Active ingredient Clinical benefits Clinical trials Launch Maturity Positioning Competition Where we measure Where each study comes in Epidemiological models Pharmacoeconomics / HEOR Patient Journey Usage & Attitudes Brand Tracker Targeting Ad hoc researchat any point
Fig. 1A medicine's route, from active ingredient to positioning. Our studies cover the market stretch.

Chapter I

Without a declared method, a finding is an expensive opinion.

From noise to sample

Data quality starts with who answers. Every filter in the figure is a real panel control.

  1. Validated professional license100 % of the roster
  2. Active clinical practice1,000+ physicians in our own panel · active roster, Jan 2026
  3. Specialty, sector and state15+ specialties · 32 states · IMSS, ISSSTE, IMSS-Bienestar and private
  4. The cohort that answersn ≥ 60 per specialty · 20 % audited · retention > 80 % per wave
  5. The reading95 % confidence intervals, every table with its base and its error
  6. The decisionwhat to do, in what priority and what gets re-measured
Fig. 2Illustrative: each dot is a possible respondent. The figures in the column are the panel's own.

Verified specialists, not rented panels

We recruit and validate every physician: professional license, specialty, institution and real consultation volume. No one joins the panel without documentary verification.

That enables something a rented panel cannot: reaching exactly the same cohort wave after wave and reading the change instead of the noise.

Typical field time: 3–6 weeks · active practice reviewed every semester

How the panel is built

The method is declared before fieldwork begins

Declared method, declared sample, findings with the decision attached. Every study ships with its protocol: what was asked, of whom, how the sample was selected and the margin of error each figure carries.

  1. Phase 01

    Design

    We translate the business question into measurable hypotheses and define universe, sampling frame, inclusion criteria and statistical power. The protocol is signed before recruitment starts.

  2. Phase 02

    Field

    Recruitment from our own panel with professional license and active practice verification. Double quality control: validation at capture and audit of 20% of interviews. We also field on the client's own panel, according to the needs and definitions of the study.

  3. Phase 03

    Analysis

    Weighting to the physician universe, declared significance testing and 95% confidence intervals. Every table travels with its base and its error level.

  4. Phase 04

    Decision

    The report closes with the action: what to do, in what priority, what gets re-measured and when. Working session with your team included.

Standards we apply

  • ISPOR for cost-effectiveness, cost-utility and budget impact models.
  • PRISMA for the systematic review feeding the epidemiological models.
  • LFPDPPP and informed consent for every personal data point collected in the field.
  • Pharmacovigilance: reporting protocol for adverse events detected during interviews.

Seven methodologies, each with a declared purpose

They are chosen by the decision in front of you, not from a catalogue. They almost always combine: one maps the terrain, another keeps it measured over time.

Who we answer to

Brand marketing

The physician receives five competing messages a week and the patient rarely arrives adherent. That is where your share is decided, and that is where we measure.

Market Access

IMSS, ISSSTE, IMSS-Bienestar and PEMEX do not buy without evidence of economic value. We build the quantitative argument that withstands review.

Medical Affairs

There is a gap between trial evidence and Mexican clinical practice. We measure it: real-world use, referral patterns and guideline adherence.

Compare the seven methodologies

Each page declares minimum sample, field timing, deliverable and the function it answers to.

  1. 01

    Targeting

    continuous platform · 4 waves/year

    Epidemiology, Usage & Attitudes, Brand Tracker and dynamic forecasting in a single living model, recalibrated every quarter against real prescription. Interactive dashboard included.

  2. 02

    Patient Journey

    ad hoc study · 8–12 weeks

    The full patient route, from symptom to 12-month adherence: diagnostic barriers, intervention windows and the points where the clinical decision is actually made.

  3. 03

    Usage & Attitudes

    quantitative · 6–10 weeks

    Real prescribing habit measured on a verified panel: choice drivers, switching barriers and perceived efficacy and safety against the competitive set.

  4. 04

    Brand Tracker

    longitudinal · quarterly wave

    Positioning measured wave after wave on a fixed panel: Top of Mind, share of prescription, NPS and brand equity, with a read on competitive movement.

  5. 05

    Epidemiological models

    modelling · 4–8 weeks

    Eligible-patient sizing by indication using ENSANUT, IMSS, Ministry of Health data and systematic review. Diagnosis-to-treatment funnel by biomarker, sector and institution.

  6. 06

    Pharmacoeconomics / HEOR

    dossier · 12–20 weeks

    Cost-effectiveness, cost-utility (QALY / ICER) and budget impact built to ISPOR standards, designed to withstand payer review.

  7. 07

    Ad hoc research

    bespoke · per design

    Message recall, copy testing, KOL mapping, advisory boards and real-world evidence. If the question does not fit a format, we design an ad hoc study from scratch.

Studies that changed a decision

Projects anonymised under confidentiality agreement. We publish the challenge, the methodology and the decision the study enabled; quantitative results remain the client's property.

15 years of team experience with global Top 10 pharmaceutical companies · results under NDA

Oncology · NSCLC

Time to confirmed diagnosis

The Patient Journey isolated a referral barrier between pulmonology and oncology. Redesigning the message to first-contact physicians shortened the patient route.

Patient Journey

Diabetes · GLP-1

Share of use

Four Brand Tracker waves caught the competitor's narrative shift a quarter before the planning cycle. The brand reacted in time.

Brand Tracker

Biologic · Access

Inclusion in institutional formulary

The pharmacoeconomic dossier withstood review and secured inclusion in the first evaluation cycle, with no round of clarifications.

Pharmacoeconomics / HEOR · ISPOR standard

See all case studies

Tell us what you need to measure.

In under 48 business hours you receive scope, methodology, proposed sample, field timing and investment range. No cost, no commitment. Request a proposal

hola@scopusconsulting.com.mx · +52 442 388 5410
Mon–Fri · 9:00–19:00 CT